Heron Therapeutics | HRTX - Assets


Heron Therapeutics reported $246.22M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amarin USD 645.76M 25.01M Mar/2026
ANI Pharmaceuticals USD 1.42B 18.41M Mar/2026
Anika Therapeutics USD 179.39M 10.88M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
Eisai JPY 1.45T 37.11B Mar/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ligand Pharmaceuticals USD 1.53B 28.53M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.21B 56.38M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Veracyte USD 1.44B 30.38M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026